Progress in the research and therapy of adult acute lymphoblastic leukemia (ALL) is
accelerating. This analysis summarizes the data derived from the clinical trials conducted at …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned …

Reverse transcription polymerase chain reaction (RT‐PCR) for BCR:: ABL1 is the most
common and widely accepted method of measurable residual disease (MRD) assessment in …

Multidrug chemotherapy has historically been the cornerstone of therapy for both children
and adults with acute lymphocytic leukaemia. However, in the past decade, several novel …

Importance In newly diagnosed Philadelphia chromosome–positive (Ph+) acute
lymphoblastic leukemia (ALL), disease progression due to acquired resistance to first-or …

Ponatinib is a third‐generation BCR:: ABL1 tyrosine kinase inhibitor (TKI) with high potency
against Philadelphia chromosome (Ph)‐positive leukemias, including T315I‐mutated …

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) constitutes a
distinctive cytogenetic entity associated with challenging outcomes, particularly in adult …

Simple Summary Remarkable strides have been performed in the treatment of adults
diagnosed with Philadelphia-positive lymphoblastic leukemia (Ph+ ALL) through the …

Acute lymphoblastic leukemia (ALL) is one of the most rapidly changing hematological
malignancies with advanced understanding of the genetic landscape, detection methods of …

Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute
lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy Characteristics …